Effects of cAMP and β-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure
Related Experiment Video
Updated: Jun 8, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Xiuqing Tian1, Lei Zhang, Yinglong Hou
1Department of Cardiology, Shandong Province Qianfoshan Hospital, Affiliated Hospital of Shandong University, Jinan, China.
Objective:
To observe the effects of cyclic adenosine monophosphate (cAMP) in peripheral lymphocytes on T helper 1 (TH1)/TH2 cytokine ratios and to investigate the potential impact and mechanism of β-adrenergic receptor antagonists on immune function in patients with chronic heart failure (CHF).
Methods:
Sixty-nine patients with New York Heart Association functional class II-IV CHF and a radionuclide left ventricular ejection fraction of less than 45% received carvedilol or metoprolol in a randomized fashion. Thirty healthy persons were studied as controls. Interferon (IFN)-γ and interleukin (IL)-10 in CD4+ T lymphocytes were quantified by three-color flow cytometry. cAMP levels in peripheral blood mononuclear cells were tested by radioimmunoassay at baseline and 6 months after treatment.
Results:
The levels of lymphocyte cAMP in CHF patients were significantly lower than in normal controls (p < 0.01). The IFN-γ/IL-10 ratio was significantly higher in CHF patients (p < 0.01). The levels of cAMP, IFN-γ and IL-10 among CHF patients with different pathogenic factors displayed no significant differences (p > 0.05). The lymphocyte cAMP level was negatively correlated with the IFN-γ/IL-10 ratio (p < 0.01). After treatment with metoprolol and carvedilol, the IFN-γ/IL-10 ratio in the CHF patients was dramatically decreased (p < 0.01 for each drug) and lymphocyte cAMP was remarkably increased (p < 0.01 for each drug).
Conclusion:
These results suggest that the decrease of cAMP affects the TH1/TH2 phenotype in peripheral lymphocytes of CHF patients. β-Blocking medications appear to have a beneficial effect on the TH1/TH2 balance and on the immune system through increasing production of cAMP, offering further evidence to support the use of β-adrenergic receptor blockers to treat CHF.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure V: Medical Management
